[Multidisciplinary therapy of urogenital cancer].
At present there is no effective chemotherapeutic agent for the treatment of renal carcinoma. In Japan there have been reports concerning group studies employing alpha and beta-type interferon (IFN) with effective results of being obtained. The treatment of advanced renal cell carcinoma is exceptionally difficult but Kato and his co-workers at Akita university have achieved good results with a chemo-embolization method employing MMC-mc. In cases of bladder cancer, there have been several reports in the international and Japanese reports concerning the relationship between prognosis and the loss of ABO blood antigens on the cellular membrane. We consider that, in it's negative cases, aggressive multidisciplinary treatment is necessary even in early stage cases. The treatment of prostate cancer is primarily based on hormone treatment but in cases of recurrence or hormone resistant cases chemotherapy including adriamycin, cyclophosphamide and cis-platin is employed but complete response is difficult to obtain. Therefore the problem is how to control such cases for as long as possible.
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D006801:Humans; D007370:Interferon Type I / Q000627:therapeutic use; D007680:Kidney Neoplasms / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D008297:Male; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D001743:Urinary Bladder / Q000601:surgery; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*
D007370:Interferon Type I